Insilico Medicine unveiled LEGION, an AI-driven drug discovery workflow covering vast chemical space around the NLRP3 inflammation target. This platform seeks to optimize new compound identification while preemptively securing intellectual property to block competitors from producing similar molecules. Applied towards an oral NLRP3 inhibitor for Parkinson’s and other diseases, LEGION exemplifies AI's dual role as a discovery and defensive tool in biotechnology innovation.